Abstract
We present the results of sequential imaging studies conducted in two patients with dilated cardiomyopathy whose responses to long-term beta-blocker therapy differed. We evaluated the time course of the myocardial clearance and the heart to upper mediastinal ratios of I-123 metaiodobenzylguanidine (MIBG) scintigraphy. In the first patient, the left ventricular ejection fraction as well as the clinical symptoms were improved by long-term beta-blocker therapy with a concurrent normalization of the myocardial clearance and the heart to upper mediastinal ratio of I-123 MIBG scintigraphy. The myocardial clearance and the upper mediastinal ratio of I-123 MIBG indicated no improvement in the second patient, and the left ventricular function did not change. The myocardial clearance and the heart to upper mediastinal ratio of I-123 MIBG scintigraphy were useful in evaluating the efficacy of long-term beta-blocker therapy in patients with dilated cardiomyopathy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blokade in congestive cardiomyopathy.Br Heart 737: 1022–1036, 1975.
Chidsey CA, Braunwald E, Morrow AG, Mason DT. Myocardial norepinephrine concentration in man: Effects of reserpine and of congestive heart failure.N Engl J Med 269: 653–659, 1963.
Pierpont GL, Francis GS, DeMaster EG, Olivari MT, Ring WS, Goldenberg IF, et al. Heterogeneous myocardial catecholamine concentrations in patients with congestive heart failure.Am J Cardiol 60: 316–321, 1987.
Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu J, Clinthorne NH. Myocardial imaging with a radioiodinated norepinephrine storage analog.J Nucl Med 22: 22–31, 1981.
Schofer J, Spielmann R, Schuchert A, Weber K, Schlüter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy.J Am Coll Cardiol 12: 1252–1258, 1988.
Momose M, Kobayashi H, Kashikura K, Kanaya S, Maki M, Hosoda S, et al. Quantitative analysis of123I-metaiodobenzylguanidine myocardial scintigraphy by myocardial uptake using a phantom.KAKU IGAKU (Jpn J Nucl Med) 31: 143–149, 1994.
Momose M, Kobayashi H, Saito K, Horie T, Maki M, Hosoda S, et al. Two cases of dilated cardiomyopathy with the relationship between the effect of (-blocker therapy and the changes of myocardial clearance of123I-metaiodobenzylguanidine.KAKU IGAKU (Jpn J Nucl Med) 32: 301–306, 1995.
Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure.Am J Cardiol 41: 233–243, 1978.
Bito K, Kubo S, Saimyoji H. Role of endocrine factors in chronic congestive heart failure, with emphasis on catecholamines.Jpn Circ J 44: 117–127, 1980.
Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lam-bert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure.Circulation 93: 1667–1676, 1996.
Nemanich JW, Veith RC, Abrass IB, Stratton JR. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy.Am J Cardiol 66: 603–307, 1990.
Gilbert EM, O’Connell JB, Bristow MR. Therapy of idiopathic dilated cardiomyopathy with chronicβ-adrenergic blockade.Heart Vessels (suppl) 6: 29–39, 1991.
Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased β-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy.Circulation 79: 483–490, 1989.
Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O’Connell JB, Renlund DG, et al. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo.Am J Med 88: 223–229, 1990.
Nakajima K, Taki J, Bunko H, Shimizu M, Muramori A, Tonami N, et al. Error of uptake in dual energy acquisition with201Tl and123I labeled radiopharmaceuticals.Eur J Nucl Med 16: 595–599, 1990.
Ichihara T, Ogawa K, Motomura N, Kubo A, Hashimoto S. Compton scatter compensation using the triple-energy window method for single- and dual-isotope SPECT.J Nucl Med 34:2216–2221, 1993.
Tsuchimochi S, Tamaki N, Tadamura E, Kawamoto M, Fujita T, Yonekura Y, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by iodine-123-MIBG imaging.J Nucl Med 36: 969–974, 1995.
Merlet P, Valette H, Dubois-Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.J Nucl Med 33:471–477, 1992.
Yamamoto K, Asada S, Yabunouchi T, Morozumi R, Kusuoka H, Nishimura T. Serial assessment of MIBG scintigraphy in a case of DCM with heart failure improved by β-blocker therapy.KAKU IGAKU (Jpn J Nucl Med) 32: 413–418, 1995.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Yamanari, H., Sakamoto, T., Takenaka, S. et al. Myocardial clearance of I-123 metaiodobenzylguanidine in dilated cardiomyopathy. Ann Nucl Med 11, 325–329 (1997). https://doi.org/10.1007/BF03165301
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03165301